Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Equity Bottom-Up

<ul><li>Natera's third-quarter performance in 2025 reflects a strong operational and financial progression, with key highlights, opportunities, and challenges to consider from an investment perspective.</li><li>The company's revenue for the quarter was reported at $592 million, reflecting a significant 35% year-over-year growth.</li><li>This substantial revenue increase is attributed primarily to strong demand for Natera’s core products and breakthrough growth in Signatera, their minimal residual disease (MRD) test, which saw a record number of processed clinical tests.</li></ul>

Natera's third-quarter performance in 2025 reflects a strong operational and financial progression, with key highlights, opportunities, and challenges to consider from an investment perspective.The company's revenue for the quarter was reported at $592 million, reflecting a significant 35% year-over-year growth.This substantial revenue increase is attributed primarily to strong demand for Natera’s core products and breakthrough growth in Signatera, their minimal residual disease (MRD) test, which saw a record number of processed clinical tests.

Natera Makes High-Conviction Moves to Seize the Lucrative Oncology Frontier; Will It Succeed?

Technical Analyst, Vermilion Research

Joe Jasper

Technical Analyst

Technical and Quantitative Research

Vermilion Research

Vermilion’s objective is to deliver timely, actionable, and unique technical research to professional investors through the application of our various technical indicators.

Our research strategists seek to highlight securities which we believe are at major inflection points, based on our various technical and quantitative indicators, and offer asymmetric risk/return profiles. Our unique research methodology, centered on relative strength, enables our strategists to deliver superior investment recommendations.

Our process begins by organizing the universe of actively traded stocks into discrete sectors, then into industry groups. We then apply our technical and quantitative tools to identify developing price trends. Once attractive trends are identified within a selected sector or group, we screen for individual stocks which we believe offer the best risk/reward profile. We provide a historical perspective that often reveals, through our long-term charts, how price patterns often repeat themselves over time.

Technical Analysis

<ul>
<li>We remain bullish (as of our 4/21/26 Compass) on the S&amp;P 500 (SPX), Nasdaq 100 (QQQ), and Russell 2000 (IWM). </li>
<li>Additionally, we continue to believe the bottom is in for SPX, IWM, QQQ, and Technology areas (XLK, IGV, SOXX, CHAT).</li>
<li>With that said, some mixed price action in A.I. themes -- notably semiconductors (SOXX), generative A.I. (CHAT), memory (DRAM), and neoclouds (WGMI) -- are giving us some reason for pause.</li>
</ul>


We remain bullish (as of our 4/21/26 Compass) on the S&amp;P 500 (SPX), Nasdaq 100 (QQQ), and Russell 2000 (IWM). 
Additionally, we continue to believe the bottom is in for SPX, IWM, QQQ, and Technology areas (XLK, IGV, SOXX, CHAT).
With that said, some mixed price action in A.I. themes -- notably semiconductors (SOXX), generative A.I. (CHAT), memory (DRAM), and neoclouds (WGMI) -- are giving us some reason for pause.


Mixed Signals in A.I. Names (SOXX, CHAT, DRAM, WGMI); Bullish Outlook Intact

Smartkarma AI Primers, Smartkarma

αSK Primers

Smartkarma AI Primers

Smartkarma

Smartkarma unites the fragmented investment industry, connecting institutional investors, independent research providers, and corporates within a single network.

Research Reinvented

<ul>
  <li>Natera is a leader in the high-growth cell-free DNA (cfDNA) testing market, with a strong portfolio spanning women's health (Panorama), oncology (Signatera), and organ health (Prospera).</li>
  <li>The company is experiencing rapid revenue growth, driven by the strong uptake of its Signatera test for cancer monitoring, and is demonstrating significant operational leverage with improving gross margins and a clear trajectory towards positive free cash flow.</li>
  <li>While the company's proprietary SNP-based technology provides a competitive advantage, Natera faces significant risks related to reimbursement uncertainty, intense competition, and the need to achieve sustained profitability after a history of net losses.</li>
</ul><p><em>This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.</em></p>


  Natera is a leader in the high-growth cell-free DNA (cfDNA) testing market, with a strong portfolio spanning women's health (Panorama), oncology (Signatera), and organ health (Prospera).
  The company is experiencing rapid revenue growth, driven by the strong uptake of its Signatera test for cancer monitoring, and is demonstrating significant operational leverage with improving gross margins and a clear trajectory towards positive free cash flow.
  While the company's proprietary SNP-based technology provides a competitive advantage, Natera faces significant risks related to reimbursement uncertainty, intense competition, and the need to achieve sustained profitability after a history of net losses.
This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

Index Rebalance and Special Situations Coverage, Quiddity Advisors

Anjana Amarasuriya

Index Rebalance and Special Situations Coverage

Quiddity Advisors

Pan-Asia Catalysts/Events

Index Rebalance

<ul>
<li>The Nasdaq 100 index tracks the 100 largest names listed on the Nasdaq Stock Exchange.</li>
<li>In this insight, we have presented our expectations for ADDs/DELs for the upcoming annual reconstitution in December 2026.</li>
<li>We expect threes changes at the December index rebal event and no intra-review changes before then.</li>
</ul>


The Nasdaq 100 index tracks the 100 largest names listed on the Nasdaq Stock Exchange.
In this insight, we have presented our expectations for ADDs/DELs for the upcoming annual reconstitution in December 2026.
We expect threes changes at the December index rebal event and no intra-review changes before then.


Quiddity Leaderboard Nasdaq100 Dec26 Rebal: 3 ADDs/DELs; US$42bn One-Way Flow

<ul>
<li>The Nasdaq 100 index tracks the 100 largest names listed on the Nasdaq Stock Exchange.</li>
<li>We expect no changes for the September 2026 index rebal event, though SpaceX's free-float increase should still drive roughly US$13bn of one-way flow.</li>
<li>We expect three ADDs and four DELs at the December 2026 annual reconstitution, with DELs necessarily exceeding ADDs by one to bring member count back to 100.</li>
</ul>


The Nasdaq 100 index tracks the 100 largest names listed on the Nasdaq Stock Exchange.
We expect no changes for the September 2026 index rebal event, though SpaceX's free-float increase should still drive roughly US$13bn of one-way flow.
We expect three ADDs and four DELs at the December 2026 annual reconstitution, with DELs necessarily exceeding ADDs by one to bring member count back to 100.


Quiddity Leaderboard Nasdaq100 Sep26 Rebal: Still No Changes in September

United States

Natera, Inc. operates as a diagnostics company. The Company provides preconception and prenatal genetic testing services. Natera also offers pre-implantation genetic diagnosis, aneuploidy screening, translocation, and single gene testing services.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Natera Inc (NTRA US)

Natera Makes High-Conviction Moves to Seize the Lucrative Oncology Frontier; Will It Succeed?

Natera's third-quarter performance in 2025 reflects a strong operational and financial progression, with key highlights, opportunities, and...

Baptista Research

Mixed Signals in A.I. Names (SOXX, CHAT, DRAM, WGMI); Bullish Outlook Intact

Mixed Signals in A.I. Names ($SOXX $CHAT $DRAM $WGMI); Bullish Outlook Intact $SPX $QQQ $IWM. $CHAT breaking above the 50-day MA likely signaling...

Vermilion Research

Primer: Natera Inc (NTRA US) - Nov 2025

Natera is a leader in the high-growth cell-free DNA (cfDNA) testing market, with a strong portfolio spanning women's health (Panorama), oncology...

αSK Primers

Quiddity Leaderboard Nasdaq100 Dec26 Rebal: 3 ADDs/DELs; US$42bn One-Way Flow

Moderna replacing WBD is the last expected intra-review change before December. The annual reconstitution should bring three more Nasdaq-100...

Anjana Amarasuriya

Quiddity Leaderboard Nasdaq100 Sep26 Rebal: Still No Changes in September

Paramount Skydance (PSKY US) will move its listing to the NYSE on 6 October 2026, and following its 21 September settlement, its acquisition of WBD...

Anjana Amarasuriya

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)